Literature DB >> 10368040

Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations.

M E Powell1, D R Collingridge, M I Saunders, P J Hoskin, S A Hill, D J Chaplin.   

Abstract

BACKGROUND AND
PURPOSE: Carbogen (95%O2, 5%CO2) is being used in clinical trials as a hypoxic radiosensitiser. Tolerance to carbogen can be a problem, this study compares tumour oxygenation during inhalation of hyperoxic gas containing either 2% or 5% CO2.
MATERIALS AND METHODS: Tumour pO2 was measured in 16 patients using the Eppendorf pO2 histograph.
RESULTS: After breathing gas containing either 5% or 2% CO2 an increase in median pO2 was measured in every tumour, the frequency of low pO2 values ( < or = 10 mmHg) fell from 47% to 29% in the 5% group and from 55% to 17% in the 2% group.
CONCLUSIONS: This study confirms that breathing 2% CO2 and 98% O2 is well tolerated and effective in increasing tumour oxygenation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368040     DOI: 10.1016/s0167-8140(98)00123-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

1.  Enhanced uptake of ifosfamide into GH3 prolactinomas with hypercapnic hyperoxic gases monitored in vivo by (31)P MRS.

Authors:  Loreta M Rodrigues; Simon P Robinson; Paul M J McSheehy; Marion Stubbs; John R Griffiths
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

2.  Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T.

Authors:  Rami R Hallac; Yao Ding; Qing Yuan; Roderick W McColl; Jayanthi Lea; Robert D Sims; Paul T Weatherall; Ralph P Mason
Journal:  NMR Biomed       Date:  2012-05-23       Impact factor: 4.044

3.  Tumor hypoxia imaging.

Authors:  Xilin Sun; Gang Niu; Nicholas Chan; Baozhong Shen; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

4.  Hypofractionated Conformal Radiotherapy (HCRT) for primary and metastatic lung cancers with small dimension : efficacy and toxicity.

Authors:  Maria Alessandra Mirri; Giorgio Arcangeli; Marcello Benassi; Annelisa d'Angelo; Valentina Pinzi; Mauro Caterino; Massimo Rinaldi; Anna Ceribelli; Lidia Strigari
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

5.  Carbogen gas-challenge BOLD MR imaging in a rat model of diethylnitrosamine-induced liver fibrosis.

Authors:  Ning Jin; Jie Deng; Tamuna Chadashvili; Yue Zhang; Yang Guo; Zhuoli Zhang; Guang-Yu Yang; Reed A Omary; Andrew C Larson
Journal:  Radiology       Date:  2010-01       Impact factor: 11.105

6.  A randomized prospective study of extended tocopherol and pentoxifylline therapy, in addition to carbogen, in the treatment of radiation late effects.

Authors:  S Brennan; O Salib; C O'Shea; M Moriarty
Journal:  Ecancermedicalscience       Date:  2008-06-09

7.  The influence of tumor oxygenation on (18)F-FDG (fluorine-18 deoxyglucose) uptake: a mouse study using positron emission tomography (PET).

Authors:  Linda W Chan; Sebastien Hapdey; Sean English; Jurgen Seidel; Joann Carson; Anastasia L Sowers; Murali C Krishna; Michael V Green; James B Mitchell; Stephen L Bacharach
Journal:  Radiat Oncol       Date:  2006-02-28       Impact factor: 3.481

8.  The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells.

Authors:  Shannon M Mumenthaler; Jasmine Foo; Nathan C Choi; Nicholas Heise; Kevin Leder; David B Agus; William Pao; Franziska Michor; Parag Mallick
Journal:  Cancer Inform       Date:  2015-07-15

9.  Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans.

Authors:  R Alonzi; A R Padhani; R J Maxwell; N J Taylor; J J Stirling; J I Wilson; J A d'Arcy; D J Collins; M I Saunders; P J Hoskin
Journal:  Br J Cancer       Date:  2009-02-03       Impact factor: 7.640

10.  In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography.

Authors:  H Barthel; H Wilson; D R Collingridge; G Brown; S Osman; S K Luthra; F Brady; P Workman; P M Price; E O Aboagye
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.